clinical trial · NCT07734844
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO
Diabetic Macular Edema (DME)Tabirafusp tedromerAflibercept (2.0 mg)
brief summary
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants with Diabetic Macular Edema - ALTO
started
Aug 3, 2026
primary completion
Aug 31, 2028
completion
Sep 1, 2029
last updated
Aug 21, 2026
official title
A Randomized, Double-masked, Active-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Tedromer 5 mg Compared With Intravitreal Aflibercept 2 mg in Participants With Visual Impairment Secondary to Diabetic Macular Edema (DME) - ALTO
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol